Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies.
PLoS One
; 16(7): e0254247, 2021.
Article
em En
| MEDLINE
| ID: mdl-34329335
ABSTRACT
Use of nicotine-specific monoclonal antibodies (mAbs) to sequester and reduce nicotine distribution to brain has been proposed as a therapeutic approach to treat nicotine addiction (the basis of tobacco use disorder). A series of monoclonal antibodies with high affinity for nicotine (nicâ¢mAbs) was isolated from B-cells of vaccinated smokers. Genes encoding 32 unique nicotine binding antibodies were cloned, and the mAbs expressed and tested by surface plasmon resonance to determine their affinity for S-(-)-nicotine. The highest affinity nicâ¢mAbs had binding affinity constants (KD) between 5 and 67 nM. The 4 highest affinity nicâ¢mAbs were selected to undergo additional secondary screening for antigen-specificity, protein properties (including aggregation and stability), and functional in vivo studies to evaluate their capacity for reducing nicotine distribution to brain in rats. The 2 most potent nicâ¢mAbs in single-dose nicotine pharmacokinetic experiments were further tested in a dose-response in vivo study. The most potent lead, ATI-1013, was selected as the lead candidate based on the results of these studies. Pretreatment with 40 and 80 mg/kg ATI-1013 reduced brain nicotine levels by 56 and 95%, respectively, in a repeated nicotine dosing experiment simulating very heavy smoking. Nicotine self-administration was also significantly reduced in rats treated with ATI-1013. A pilot rat 30-day repeat-dose toxicology study (4x200mg/kg ATI-1013) in the presence of nicotine indicated no drug-related safety concerns. These data provide evidence that ATI-1013 could be a potential therapy for the treatment of nicotine addiction.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tabagismo
/
Encéfalo
/
Anticorpos Monoclonais
/
Afinidade de Anticorpos
/
Nicotina
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article